Adalta Ltd has released a press release.
FDA Orphan Drug Designation for AD-214
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from AdAlta
- Phase I HV extension to explore encouraging results
- AGM Presentation
- AusBiotech presentation including Phase I status update
- Investor Presentation - BIO investor forum
- GE Healthcare collaboration progresses
Later from AdAlta
- Appendix 4D and Interim Financial Report
- Investor briefing-AD-214 top line single dose safety results
- Mutiple Dose Part Of Ad-214 Phase I Trial Commenced
- AdAlta granted Japanese patent for AD-214
- GE Healthcare collaboration advances to next stage
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta